Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:52 20/05/2024 am IST			5-day change	1st Jan Change
1.075 ^AUD	-0.92%		+2.87%	+246.77%

01/04	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
28/03	ADRs End Lower; NuCana Slides 15%	DJ

Donal O'Dwyer Retires from the Board of Mesoblast Limited

February 25, 2022 at 03:03 am IST

As foreshadowed at the Annual General Meeting in November 2021, the two long standing non-executive directors will retire from the Board over a 6-12 month period. As such, Mr. Donal O'Dwyer retires from the Board of Mesoblast Limited on February 24, 2022.

Latest news about Mesoblast Limited

ADRs End Higher; Connect Biopharma Climbs 26%	02/04	DJ
ADRs End Lower; NuCana Slides 15%	29/03	DJ
ADRs End Lower; Quhuo Drops 53%	27/03	DJ
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission	27/03	MT
Sector Update: Health Care Stocks Advance Late Afternoon	27/03	MT
Top Midday Gainers	26/03	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	26/03	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26/03	MT
Top Premarket Gainers	26/03	MT
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application	26/03	DJ
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	26/03	MT
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	26/03	CI
Mesoblast Limited(ASX:MSB) added to S&P/ASX Emerging Companies Index	18/03	CI
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement	14/03	MT
Mesoblast Raises AU$97 Million for Phase Three Registration Trials	14/03	MT
Sector Update: Health Care Stocks Softer Late Afternoon	12/03	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	11/03	MT
Sector Update: Health Care	11/03	MT
Top Stories at Midday: Bally's Gets Takeover Proposal; Eli Lilly's Eczema Study Results; Reddit's Expected IPO Price Range; FDA Backs Mesoblast Heart Therapy's Approval Pathway	11/03	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	11/03	MT
Mesoblast Says FDA Supports Accelerated Approval Pathway for Heart Failure Treatment	11/03	MT
Mesoblast Secures Backing from US FDA for Potential Fast-Track Approval of Heart Failure Treatment	11/03	MT
Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device	11/03	CI
Mesoblast Narrows H1 FY24 Loss; Shares Down 3%	29/02	MT
Transcript : Mesoblast Limited, Q2 2024 Earnings Call, Feb 28, 2024	29/02

Chart Mesoblast Limited

Duration

Period

More charts

Company Profile

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Companyâs Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Companyâs licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Sector

Biotechnology & Medical Research

Calendar

29/05/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mesoblast Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.085 AUD

Average target price

1.1 AUD

Spread / Average Target

+1.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MESOBLAST LIMITED	+246.77%	83Cr
MODERNA, INC.	+33.63%	5.09TCr
IQVIA HOLDINGS INC.	-0.09%	4.21TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.92TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.6TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.89TCr
BIO-TECHNE CORPORATION	+8.61%	1.32TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.22TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr

Other Biotechnology & Medical Research